Positioned to transform the HBV treatment landscape and address the HBV global market opportunity
Portfolio of assets combining multiple technologies aimed at curing HBV
Proven scientific leadership in antiviral and RNAi drug discovery and development
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of Non-HBV Assets that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.
Arbutus' portfolio of assets includes three distinct pipelines of products in development: one focused HBV Assets, one on Non-HBV Assets and one on Partnered Programs
